Total
0
Shares
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito - The Market Herald
President & Executive Chairman, Vince Ippolito
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Botanix Pharmaceuticals (BOT) says it has received encouraging results from a small pilot study of its synthetic CBD treatment in canines with atopic dermatitis
  • The objective of the study was the evaluate the effectiveness of the higher dose formulation of synthetic CBD on four dogs in Australia who were screened for moderate to severe dermatitis with visible lesions
  • The company says the results of the study are encouraging and warrant expansion of the program into a larger proof of concept canine study, planned for Q2 2021
  • Should this study be successful, a phase 2b clinical study in humans with atopic dermatitis could commence as early as Q2 2022
  • Botanix Pharmaceuticals' shares are up a slight 1.28 per cent to trade at 7.9 cents

Botanix Pharmaceuticals (BOT) says it has received encouraging results from a small pilot study of its synthetic CBD treatment in canines with atopic dermatitis.

The BTX 1204A pilot study was conducted in canines with atopic dermatitis, a condition that makes skin red, cracked and itchy, with treatments applied over 28 days. 

The objective of the study was to evaluate the effectiveness of the higher dose formulation of synthetic CBD, using the enhanced pruritus score (ESP) and canine atopic dermatitis extent and severity index (CADESI-04) to measure its success.

The study was conducted in four dogs in Australia who were screened for moderate to severe dermatitis with visible lesions. The new formulation was previously used in the company’s BTX 1801 phase 2a study and demonstrated excellent efficacy in killing bacteria.

Data from the study showed the higher dose formulation of synthetic CBD provided significant reductions on average in both the ESP and CADESI-04 scores over the 28-day treatment period.

According to Botanix, 31.6 million people in the U.S. have some form of atopic dermatitis, with one in 10 people developing symptoms during their lifetime.

"We are very encouraged that we are seeing early positive efficacy signals for BTX 1204A in canines with atopic dermatitis," President and Executive Chairman Vince Ippolito said.

'We are now in advance stages in planning to complete a larger BTX 1204A proof of concept canine study in Australia, with the primary objective to confirm and expand our data for safety and efficacy."

The company says the results of the study are encouraging and warrant expansion of the program into a larger proof of concept canine study, planned for Q2 2021.

Should this study be successful, a phase 2b clinical study in humans with atopic dermatitis could commence as early as Q2 2022.

Botanix Pharmaceuticals' shares are up 1.28 per cent and are trading at 7.9 cents at 10:31 am AEST.

BOT by the numbers
More From The Market Herald
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) completes US dual listing

Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange.
The Market Herald Video

" US regulator approves expanded use of Avita Medical’s (ASX:AVH) RECELL System

The US regulator has approved the expanded use of Avita Medical’s (AVH) RECELL system in combination with meshed autographs to treat burns patients.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac - The Market Herald

" Advanced Human Imaging (ASX:AHI) signs term sheet with Cubert

Advanced Human Imaging (AHI) has signed a binding term sheet with Toronto-based digital health provider Cubert Inc.
Microequities Asset Management (ASX:MAM) posts 140pc boost to half-yearly profit

" Patrys (ASX:PAB) receives $600k R&D tax incentive refund

Patrys (PAB), through its wholly owned Nucleus Therapeutics subsidiary, has received a research and development (R&D) tax incentive refund of $626,780 for the